Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jan;65(1):27–32. doi: 10.1038/bjc.1992.5

Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill.

D W Wilbur 1, E S Camacho 1, D A Hilliard 1, P L Dill 1, L M Weisenthal 1
PMCID: PMC1977362  PMID: 1310250

Abstract

Specimens from 45 patients with previously-untreated non-small cell lung cancer (NSCLC) were tested for in vitro chemosensitivity to ten drugs utilising the DiSC assay, which measures cell kill in the total (largely non-dividing) tumour cell population. Thirty-five assays were successful and 25 patients with advanced disease subsequently received chemotherapy with the 'best' three drugs selected by the assay. Six patients were Karnofsky performance status 60 or less and the median pretreatment weight loss was 8.5%. Nine patients had a partial response (response rate = 36%; 95% confidence interval = 17-55%) and the median survival of all patients was 202 days. Specimens from responding patients were significantly more sensitive in the assay to drugs in general (especially to etoposide and to 'natural product' drugs) and to the drugs used in treatment than were specimens from non-responding patients. In vitro drug resistance differences between responding and non-responding patients were of greater significance than were differences between other clinical and laboratory measurements. Assay results classified patients into two cohorts, having relatively high and low probabilities of responding to chemotherapy. Assay results also identified patient cohorts with above average and below average durations of survival. Five patients (20%) were found to have tumours with extreme drug resistance (EDR), defined as assay results for the average of all ten tested drugs falling greater than one standard deviation more resistant than the median for all tumours assayed, and none of these patients with EDR responded to chemotherapy.

Full text

PDF
27

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beksac M., Kansu E., Kars A., Ibrahimoglu Z., Firat D. A rapid drug sensitivity assay for neoplasmatic cells. Med Oncol Tumor Pharmacother. 1988;5(4):253–257. doi: 10.1007/BF03003193. [DOI] [PubMed] [Google Scholar]
  2. Berger N. A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985 Jan;101(1):4–15. [PubMed] [Google Scholar]
  3. Bird M. C., Bosanquet A. G., Forskitt S., Gilby E. D. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res. 1986;10(4):445–449. doi: 10.1016/0145-2126(86)90075-5. [DOI] [PubMed] [Google Scholar]
  4. Bosanquet A. G., Bird M. C., Price W. J., Gilby E. D. An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemia. Br J Cancer. 1983 Jun;47(6):781–789. doi: 10.1038/bjc.1983.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bosanquet A. G. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet. 1991 Mar 23;337(8743):711–714. doi: 10.1016/0140-6736(91)90287-y. [DOI] [PubMed] [Google Scholar]
  6. Campling B. G., Pym J., Galbraith P. R., Cole S. P. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk Res. 1988;12(10):823–831. doi: 10.1016/0145-2126(88)90036-7. [DOI] [PubMed] [Google Scholar]
  7. Carson D. A., Seto S., Wasson D. B., Carrera C. J. DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res. 1986 Jun;164(2):273–281. doi: 10.1016/0014-4827(86)90028-5. [DOI] [PubMed] [Google Scholar]
  8. Ganz P. A., Figlin R. A., Haskell C. M., La Soto N., Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer. 1989 Apr 1;63(7):1271–1278. doi: 10.1002/1097-0142(19890401)63:7<1271::aid-cncr2820630707>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  9. Gazdar A. F., Steinberg S. M., Russell E. K., Linnoila R. I., Oie H. K., Ghosh B. C., Cotelingam J. D., Johnson B. E., Minna J. D., Ihde D. C. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 1990 Jan 17;82(2):117–124. doi: 10.1093/jnci/82.2.117. [DOI] [PubMed] [Google Scholar]
  10. Graziano S. L., Mazid R., Newman N., Tatum A., Oler A., Mortimer J. A., Gullo J. J., DiFino S. M., Scalzo A. J. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol. 1989 Oct;7(10):1398–1406. doi: 10.1200/JCO.1989.7.10.1398. [DOI] [PubMed] [Google Scholar]
  11. Hanauske A. R., Hanauske U., von Hoff D. D. Recent improvements in the human tumor cloning assay for sensitivity testing of antineoplastic agents. Eur J Cancer Clin Oncol. 1987 Jun;23(6):603–605. doi: 10.1016/0277-5379(87)90253-7. [DOI] [PubMed] [Google Scholar]
  12. Hanauske A. R., Von Hoff D. D. The value of the human tumor cloning assay in ovarian cancer. Clin Obstet Gynecol. 1986 Sep;29(3):638–646. [PubMed] [Google Scholar]
  13. Hansen H. H. Advanced non-small-cell lung cancer: to treat or not to treat? J Clin Oncol. 1987 Nov;5(11):1711–1712. doi: 10.1200/JCO.1987.5.11.1711. [DOI] [PubMed] [Google Scholar]
  14. Kern D. H., Weisenthal L. M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst. 1990 Apr 4;82(7):582–588. doi: 10.1093/jnci/82.7.582. [DOI] [PubMed] [Google Scholar]
  15. Kirkpatrick D. L., Duke M., Goh T. S. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res. 1990;14(5):459–466. doi: 10.1016/0145-2126(90)90033-6. [DOI] [PubMed] [Google Scholar]
  16. Lathan B., von Tettau M., Verpoort K., Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transfus. 1990;33:295–298. doi: 10.1007/978-3-642-74643-7_53. [DOI] [PubMed] [Google Scholar]
  17. Link K. H., Aigner K. R., Kuehn W., Schwemmle K., Kern D. H. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res. 1986 Sep;46(9):4837–4840. [PubMed] [Google Scholar]
  18. Mulshine J. L., Glatstein E., Ruckdeschel J. C. Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov;4(11):1704–1715. doi: 10.1200/JCO.1986.4.11.1704. [DOI] [PubMed] [Google Scholar]
  19. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  20. Rotman B., Teplitz C., Dickinson K., Cozzolino J. P. Individual human tumors in short-term micro-organ cultures: chemosensitivity testing by fluorescent cytoprinting. In Vitro Cell Dev Biol. 1988 Nov;24(11):1137–1146. doi: 10.1007/BF02620817. [DOI] [PubMed] [Google Scholar]
  21. Salmon S. E. Improved methodology for chemosensitivity testing? J Clin Oncol. 1987 Dec;5(12):1861–1863. doi: 10.1200/JCO.1987.5.12.1861. [DOI] [PubMed] [Google Scholar]
  22. Scheithauer W., Moyer M. P., Clark G. M., Von Hoff D. D. Application of a new preclinical drug screening system for cancer of the large bowel. Cancer Chemother Pharmacol. 1988;21(1):31–34. doi: 10.1007/BF00262734. [DOI] [PubMed] [Google Scholar]
  23. Sondak V. K., Bertelsen C. A., Kern D. H., Morton D. L. Evolution and clinical application of a rapid chemosensitivity assay. Cancer. 1985 Mar 15;55(6):1367–1371. doi: 10.1002/1097-0142(19850315)55:6<1367::aid-cncr2820550634>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  24. Tidefelt U., Sundman-Engberg B., Rhedin A. S., Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol. 1989 Nov;43(5):374–384. doi: 10.1111/j.1600-0609.1989.tb00323.x. [DOI] [PubMed] [Google Scholar]
  25. Von Hoff D. D., Casper J., Bradley E., Sandbach J., Jones D., Makuch R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med. 1981 May;70(5):1027–1041. doi: 10.1016/0002-9343(81)90859-7. [DOI] [PubMed] [Google Scholar]
  26. Von Hoff D. D. In vitro predictive testing: the sulfonamide era. Int J Cell Cloning. 1987 May;5(3):179–190. doi: 10.1002/stem.5530050302. [DOI] [PubMed] [Google Scholar]
  27. Weisenthal L. M. Clones, dyes, nuclides, mouse kidneys, and ... virions: a new-clonogenic assay for tumor chemosensitivity. Eur J Cancer Clin Oncol. 1987 Jan;23(1):9–12. doi: 10.1016/0277-5379(87)90412-3. [DOI] [PubMed] [Google Scholar]
  28. Weisenthal L. M., Dill P. L., Finklestein J. Z., Duarte T. E., Baker J. A., Moran E. M. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep. 1986 Nov;70(11):1283–1295. [PubMed] [Google Scholar]
  29. Weisenthal L. M., Dill P. L., Kurnick N. B., Lippman M. E. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res. 1983 Jan;43(1):258–264. [PubMed] [Google Scholar]
  30. Weisenthal L. M., Lalude A. O., Miller J. B. In vitro chemosensitivity of human bladder cancer. Cancer. 1983 Apr 15;51(8):1490–1496. doi: 10.1002/1097-0142(19830415)51:8<1490::aid-cncr2820510823>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  31. Weisenthal L. M., Lippman M. E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep. 1985 Jun;69(6):615–632. [PubMed] [Google Scholar]
  32. Weisenthal L. M., Marsden J. A., Dill P. L., Macaluso C. K. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 1983 Feb;43(2):749–757. [PubMed] [Google Scholar]
  33. Weisenthal L. M., Shoemaker R. H., Marsden J. A., Dill P. L., Baker J. A., Moran E. M. In vitro chemosensitivity assay based on the concept of total tumor cell kill. Recent Results Cancer Res. 1984;94:161–173. doi: 10.1007/978-3-642-82295-7_16. [DOI] [PubMed] [Google Scholar]
  34. Weisenthal L. M., Su Y. Z., Duarte T. E., Nagourney R. A. Non-clonogenic, in vitro assays for predicting sensitivity to cancer chemotherapy. Prog Clin Biol Res. 1988;276:75–92. [PubMed] [Google Scholar]
  35. Woods R. L., Williams C. J., Levi J., Page J., Bell D., Byrne M., Kerestes Z. L. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990 Apr;61(4):608–611. doi: 10.1038/bjc.1990.135. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES